logo
Share SHARE
FONT-SIZE Plus   Neg

Genentech's Perjeta Regimen Gets Priority Review For HER2-Positive Breast Cancer

Genentech, a member of the Roche Group (RHHBY.PK), reported that the U.S. Food and Drug Administration or FDA has accepted the company's supplemental Biologics License Application or sBLA for the use of a Perjeta regimen before surgery in people with HER2-positive early stage breast cancer. The FDA has granted a Priority Review of the application and would decide on approval by October 31, 2013.

Neoadjuvant therapy, a treatment option given after diagnosis but before surgery for early stage breast cancer, aims to reduce a tumor's size so it may be easier to surgically remove, or to allow for breast-conserving surgery. Perjeta is a personalized medicine that targets the HER2 receptor, a protein found in high quantities on the outside of cancer cells in HER2-positive cancers. The combination of Perjeta, Herceptin and docetaxel chemotherapy is thought to provide a more comprehensive blockade of HER signaling pathways, Genentech added.

A priority review designation is awarded to medicines that the FDA hopes to have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease. The application is based mainly on results from NEOSPHERE and TRYPHAENA, two Phase II studies of Perjeta in HER2-positive early stage breast cancer, and on longer-term safety data from the Phase III CLEOPATRA trial of Perjeta in HER2-positive metastatic breast cancer.

The TRYPHAENA study is a randomized, multicenter Phase II trial that was conducted in 225 people with HER2-positive, locally advanced, inflammatory or early stage breast cancer.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Struggling fast-food giant McDonald's is trying to woo back customers to its stores with a new concept called "Experience of the Future." According to reports, as part of its "Experience of the Future" initiative McDonald's is planning to upgrade and renovate its restaurants that will provide modern... Facebook might be launching smart speakers with a touch panel next year. The touch screen could be used for 15-inch display of imageries. According to reports Facebook has already begun the pilot production in China. The new device is expected to be launched in the first quarter of 2018. Britain is the latest nation to announce that it will end the sale of new petrol and diesel cars in an effort to reduce air pollution. Britain said it will ban the sale of new petrol and diesel cars from 2040. In early July, France said it plans to end sales of all petrol and diesel vehicles in the country by 2040 as part of a plan to meet its targets under the Paris climate accord.
comments powered by Disqus
Follow RTT